#1 Clinical Trials Search in Europe

ENSIFENTRINE

Ensifentrine (formerly known as RPL554) is an innovative investigational drug that is being studied extensively for its potential benefits in treating respiratory conditions, primarily Chronic Obstructive Pulmonary Disease (COPD). As a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), ensifentrine works through a unique mechanism of action that combines bronchodilator effects with anti-inflammatory properties. This article explores the ongoing clinical trials examining ensifentrine’s safety, efficacy, and potential role in the treatment landscape for patients with respiratory conditions.

Table of Contents

What is Ensifentrine?

Ensifentrine (formerly known as RPL554) is an innovative medication being developed for the treatment of respiratory conditions, primarily Chronic Obstructive Pulmonary Disease (COPD). It represents a novel class of drug that works differently from existing COPD treatments [1]. What makes ensifentrine unique is its dual inhibitory action on two important enzymes in the body.

This medication is currently in the advanced stages of clinical development, with multiple Phase II and Phase III studies showing promising results for patients with moderate to severe COPD who may not be achieving adequate symptom control with standard treatments [2].

How Does Ensifentrine Work?

Ensifentrine works through a dual mechanism of action that makes it distinct from other COPD medications. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes [3]. These enzymes play important roles in regulating the inflammatory response in the airways and controlling muscle function in the lungs.

Specifically:

  • PDE3 inhibition provides bronchodilator effects, which means it helps open the airways to improve breathing [3]
  • PDE4 inhibition delivers anti-inflammatory properties, helping to reduce inflammation in the airways [3]

This combined effect is particularly valuable because COPD involves both narrowing of the airways (bronchospasm) and chronic inflammation. By addressing both components simultaneously, ensifentrine offers a comprehensive approach to COPD treatment [4].

Additionally, there is evidence suggesting that the dual inhibition of PDE3 and PDE4 can have additive or synergistic effects, potentially making the medication more effective than single-action treatments [4].

Conditions Treated by Ensifentrine

Ensifentrine is primarily being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD), a progressive lung disease that causes breathing difficulties and is commonly associated with smoking [5]. Multiple clinical trials have focused on patients with moderate to severe COPD, where there is significant need for improved treatment options.

Beyond COPD, ensifentrine is also being investigated for other respiratory conditions:

  • Cystic Fibrosis: Research has examined the pharmacokinetics (how the drug moves through the body) of ensifentrine in adult patients with cystic fibrosis [6]
  • Non-Cystic Fibrosis Bronchiectasis (NCFBE): Studies are evaluating ensifentrine’s effects on pulmonary exacerbations, symptoms, and quality of life in patients with this condition [7]
  • Asthma: Clinical trials have compared ensifentrine with other asthma treatments like salbutamol and placebo [8]
  • COVID-19: A pilot study investigated ensifentrine’s potential benefits for hospitalized COVID-19 patients [9]

This broad investigation into multiple respiratory conditions highlights the potential versatility of ensifentrine’s mechanism of action in addressing various inflammatory and bronchoconstrictive respiratory disorders.

How Ensifentrine is Administered

Ensifentrine is being developed in several formulations to provide flexibility in how it can be administered to patients. The primary formulations under investigation include:

  • Nebulizer suspension: The most extensively studied delivery method, where the medication is converted into a fine mist that patients inhale through a nebulizer device. The standard therapeutic dose in most Phase III trials is 3 mg twice daily [2][5]
  • Pressurized Metered Dose Inhaler (pMDI): A portable inhaler device that delivers a precise, measured amount of medication in aerosol form [10]
  • Dry Powder Inhaler (DPI): Another portable option where the medication is in dry powder form, activated by the patient’s inhalation [11]

The development of multiple delivery systems aims to accommodate different patient preferences and clinical situations. For example, nebulizers might be preferred for patients with severe disease or during hospital stays, while portable inhalers offer convenience for daily use [10][11].

In most clinical trials, ensifentrine is administered twice daily (BID), with each nebulization taking approximately 5 minutes [2].

Clinical Efficacy

Clinical trials have demonstrated several beneficial effects of ensifentrine in COPD patients, including:

Improved Lung Function

Multiple studies have shown that ensifentrine significantly improves FEV1 (Forced Expiratory Volume in 1 second), which is a key measure of lung function [12][5]. Improvements have been demonstrated in:

  • Peak FEV1: The maximum improvement in lung function after taking the medication [12]
  • Average FEV1 AUC0-12h: The sustained effect over 12 hours, which indicates how well the medication works throughout the day [5]
  • Morning trough FEV1: Lung function measured before taking the next dose, showing the medication’s lasting effect [12]

Symptom Improvement

Patients taking ensifentrine have reported improvements in COPD symptoms as measured by standardized questionnaires such as:

  • E-RS (Evaluating-Respiratory Symptoms): A measure of daily respiratory symptoms [5]
  • SGRQ (St. George’s Respiratory Questionnaire): Assesses health-related quality of life [5]
  • TDI (Transition Dyspnea Index): Measures changes in breathlessness [5]
  • CAT (COPD Assessment Test): Evaluates the impact of COPD on daily life [13]

These improvements in patient-reported outcomes are particularly important as they reflect real-world benefits that patients experience in their daily lives.

Reduced Need for Rescue Medication

Studies have shown that patients taking ensifentrine typically require less rescue medication (such as albuterol/salbutamol) for immediate symptom relief, indicating better overall control of their COPD [5].

Anti-inflammatory Effects

In addition to bronchodilation, ensifentrine has demonstrated anti-inflammatory properties. Research has examined its effects on inflammatory markers in sputum, including neutrophils and specific proteins like Acetylated Proline-Glycine-Proline (AcPGP) that are associated with inflammation in COPD [14].

Combination Therapy with Other COPD Medications

An important aspect of ensifentrine’s clinical development is its potential use in combination with standard COPD treatments. Several studies have specifically examined ensifentrine as an add-on therapy to:

  • Long-acting muscarinic antagonists (LAMAs) such as tiotropium: Studies have shown additional bronchodilator effects when ensifentrine is added to tiotropium [15]
  • LAMA/LABA combinations (tiotropium/olodaterol): Research indicates ensifentrine can provide further benefits when added to this dual bronchodilator therapy [16]
  • Short-acting bronchodilators like salbutamol and ipratropium: Ensifentrine has shown additive effects when used with these “reliever” medications [17]

Additionally, fixed-dose combination products are under development, particularly an ensifentrine-glycopyrrolate fixed-dose combination, which combines ensifentrine with a LAMA in a single formulation [18][19].

These combination approaches are particularly important because many COPD patients remain symptomatic despite using standard treatments, and additional therapeutic options are needed to improve their quality of life and lung function.

Safety Profile

Understanding the safety profile of any new medication is crucial, particularly for chronic conditions like COPD where treatments may be used long-term. Clinical trials of ensifentrine have provided important information about its safety and tolerability:

General Safety Findings

Multiple Phase II and Phase III studies have shown that ensifentrine is generally well-tolerated across different doses and formulations [12][5]. The safety profile has been studied in both short-term and longer-term (up to 48 weeks) treatment periods [5].

Cardiovascular Effects

Since PDE3 inhibitors can potentially affect heart function, careful monitoring of cardiovascular parameters has been included in ensifentrine trials. Studies have evaluated:

  • Blood pressure changes
  • Heart rate/pulse rate
  • ECG parameters, including QTcF intervals (a measure of cardiac electrical activity)

These assessments have not identified significant safety concerns at the therapeutic doses tested [12][5].

Gastrointestinal Effects

Oral PDE4 inhibitors have historically been associated with gastrointestinal side effects such as nausea, vomiting, and diarrhea. However, the inhaled delivery of ensifentrine appears to result in a more favorable side effect profile compared to oral PDE inhibitors [4].

Laboratory Assessments

Clinical trials have included comprehensive laboratory testing to monitor for any effects on:

  • Hematology (blood cell counts)
  • Blood chemistry (including liver and kidney function tests)
  • Urinalysis

These tests have been part of the safety monitoring in clinical trials, with no significant safety signals identified [12].

Ongoing Research and Future Applications

Ensifentrine continues to be actively investigated across multiple areas:

Expanded COPD Studies

Phase III trials are ongoing to further confirm the efficacy and safety of ensifentrine in larger populations of COPD patients, including:

  • The effect on COPD symptoms measured by the CAT score over 12 weeks [13]
  • Long-term safety and efficacy assessments (up to 48 weeks) [5]

New Delivery Systems

Development of alternative delivery systems continues, including:

  • Optimizing the pMDI formulation [10]
  • Refining the dry powder inhaler version [11]

Fixed-Dose Combinations

Research is advancing on fixed-dose combinations, particularly:

  • Ensifentrine-glycopyrrolate combinations at various dose levels [19]

Additional Respiratory Conditions

Beyond COPD, ensifentrine is being studied for:

  • Non-cystic fibrosis bronchiectasis in a Phase II study examining its effects on pulmonary exacerbations, symptoms, and quality of life [7]

These ongoing research efforts aim to establish ensifentrine’s place in the treatment landscape for COPD and potentially other respiratory conditions, providing new options for patients who may not achieve adequate symptom control with existing therapies.

Aspect Details
Drug Mechanism Ensifentrine (formerly RPL554) is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), providing both bronchodilator and anti-inflammatory effects.
Primary Conditions Studied – Chronic Obstructive Pulmonary Disease (COPD) – primary focus
– Non-cystic Fibrosis Bronchiectasis
– Cystic Fibrosis
– Asthma
– COVID-19 (exploratory)
Administration Methods – Nebulized suspension (most common in trials)
– Metered dose inhaler (pMDI)
– Dry powder inhaler (DPI)
– Fixed-dose combinations with other bronchodilators
Common Dosages – 3 mg twice daily (most common in Phase 3 trials)
– Dose range studied: 0.375 mg to 6 mg
– Fixed-dose combinations with glycopyrrolate
Primary Outcome Measures – Lung function (FEV1)
– Peak FEV1 (maximum improvement)
– Average FEV1 AUC0-12h (area under the curve over 12 hours)
– Morning trough FEV1
– Symptom scores (E-RS, SGRQ, CAT, TDI)
Trial Designs – Phase 1: Single/multiple ascending dose studies
– Phase 2: Dose-ranging studies, combination with standard therapies
– Phase 3: 24-week efficacy and safety studies
– Various designs: crossover, parallel group, placebo-controlled
Combination Studies – With tiotropium (LAMA)
– With tiotropium/olodaterol (LAMA/LABA)
– With glycopyrrolate (LAMA) as fixed-dose combination
– Added to standard COPD therapies
Study Populations – Healthy volunteers (early-phase studies)
– Patients with moderate to severe COPD
– Chinese subjects (pharmacokinetic studies)
– Patients with bronchiectasis
– Patients with cystic fibrosis

FAQ

  • What is ensifentrine and how does it work? Ensifentrine (formerly called RPL554) is an investigational medication that works as a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4). PDE3 inhibition provides bronchodilator effects (helps open airways), while PDE4 inhibition offers anti-inflammatory benefits. This dual action makes ensifentrine unique compared to many existing respiratory medications. It is primarily being studied as a nebulized treatment for patients with COPD and other respiratory conditions.
  • What conditions is ensifentrine being studied for? Ensifentrine is primarily being studied for Chronic Obstructive Pulmonary Disease (COPD), a progressive lung disease that causes breathing difficulties. Recent clinical trials have also investigated its potential in non-cystic fibrosis bronchiectasis (NCFBE), cystic fibrosis, and asthma. Some research has even explored its potential application in COVID-19 patients. The majority of advanced clinical trials focus on COPD treatment, where ensifentrine may help improve lung function and reduce symptoms.
  • What benefits might ensifentrine provide over existing treatments? Ensifentrine may offer several potential advantages over existing treatments. Its dual action as both a bronchodilator and anti-inflammatory agent could provide more comprehensive symptom relief with a single medication. Clinical trials have shown promising results when ensifentrine is used alone or combined with standard treatments like tiotropium (a long-acting muscarinic antagonist) or other bronchodilators. This suggests it might be effective for patients who remain symptomatic despite standard therapies. Additionally, inhaled administration may result in fewer systemic side effects compared to oral medications.
  • How is ensifentrine administered to patients? Ensifentrine is being studied in several formulations, but most commonly as a nebulized suspension that patients inhale. A nebulizer turns the liquid medication into a fine mist that can be breathed directly into the lungs. The typical dosing in clinical trials has been twice daily (BID), with common doses ranging from 0.375 mg to 6 mg, though 3 mg twice daily appears to be the most common dose in Phase 3 trials. Researchers are also exploring other delivery methods, including metered dose inhalers (pMDI) and dry powder inhalers (DPI), which might provide more convenient options for patients in the future.
  • What side effects have been observed with ensifentrine in clinical trials? While comprehensive safety data continues to be collected, clinical trials have generally shown ensifentrine to be well-tolerated. Researchers carefully monitor for potential effects on vital signs (such as heart rate and blood pressure), ECG parameters, and laboratory values. Common measurements in safety evaluations include monitoring for changes in QTcF interval on ECG, pulse rate, blood pressure, and routine blood tests. Safety information is particularly important because some older PDE4 inhibitors taken orally have been associated with side effects like nausea, vomiting, and gastrointestinal issues. The inhaled route of administration for ensifentrine may help reduce these types of systemic side effects.

Ongoing Clinical Trials on ENSIFENTRINE

  • Study on the Effects of Ensifentrine for Patients with Non-Cystic Fibrosis Bronchiectasis

    Recruiting

    1
    Investigated drugs:
    Italy Spain

Glossary

  • COPD (Chronic Obstructive Pulmonary Disease): A progressive lung disease characterized by persistent respiratory symptoms and airflow limitation, typically caused by significant exposure to harmful particles or gases. The main symptoms include shortness of breath, chronic cough, and sputum production.
  • PDE3/PDE4 inhibitor: A type of medication that blocks the action of phosphodiesterase enzymes type 3 and 4, which are involved in regulating inflammatory responses and airway muscle tone. Dual inhibition can provide both bronchodilator effects (PDE3) and anti-inflammatory benefits (PDE4).
  • Bronchodilator: A medication that relaxes the muscles around the airways, making breathing easier by widening the airways (bronchi) in the lungs.
  • FEV1 (Forced Expiratory Volume in 1 second): The volume of air that can be forcibly exhaled from the lungs in the first second after a full inhalation. It's a key measurement of lung function used in diagnosing and monitoring respiratory conditions.
  • AUC (Area Under the Curve): A measurement used in clinical trials to evaluate drug exposure over time. In COPD studies, FEV1 AUC refers to the average improvement in lung function over a specific period (e.g., AUC0-12h means averaged over 12 hours).
  • Peak FEV1: The maximum improvement in FEV1 observed after administration of a medication, typically measured over several hours post-dose.
  • Trough FEV1: The FEV1 measurement taken just before the next scheduled dose of medication, representing the minimum drug effect between doses.
  • Nebulizer: A device that converts liquid medication into a fine mist that can be inhaled directly into the lungs through a mouthpiece or mask.
  • pMDI (pressurized Metered Dose Inhaler): A handheld device that delivers a specific amount of medication in aerosol form through a mouthpiece using a propellant.
  • DPI (Dry Powder Inhaler): A device that delivers medication in dry powder form to the lungs when the patient inhales through the mouthpiece.
  • Pharmacokinetics (PK): The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how drugs affect the body, including their mechanism of action and the relationship between drug concentration and effect.
  • SGRQ (St. George's Respiratory Questionnaire): A standardized questionnaire designed to measure health-related quality of life in patients with respiratory disease, with scores ranging from 0-100 (higher scores indicate worse health status).
  • E-RS (Evaluating-Respiratory Symptoms): A patient-reported outcome tool derived from the EXACT-PRO questionnaire that measures the severity of respiratory symptoms in COPD patients.
  • TDI (Transition Dyspnea Index): A tool used to measure changes in breathlessness (dyspnea) from baseline, with scores ranging from -3 (major deterioration) to +3 (major improvement).
  • CAT (COPD Assessment Test): An 8-item questionnaire that measures the impact of COPD on a person's life and well-being, with scores ranging from 0-40 (higher scores indicate more severe impact).
  • FVC (Forced Vital Capacity): The total amount of air that can be forcibly exhaled after taking the deepest breath possible.
  • Non-cystic Fibrosis Bronchiectasis (NCFBE): A chronic lung condition characterized by permanent widening of the airways (bronchi) leading to excess mucus production and recurring infections, not caused by cystic fibrosis.
  • LAMA (Long-Acting Muscarinic Antagonist): A type of bronchodilator medication that blocks muscarinic receptors in the airways, leading to relaxation of airway smooth muscle and improved airflow. Examples include tiotropium.
  • LABA (Long-Acting Beta-2 Agonist): A type of bronchodilator medication that stimulates beta-2 receptors in airway smooth muscle, causing relaxation and improved airflow. Examples include salmeterol and olodaterol.
  • Fixed-Dose Combination (FDC): A medication that contains two or more active pharmaceutical ingredients combined in a fixed ratio in a single dosage form.

References

  1. https://clinicaltrials.gov/study/NCT04542057
  2. https://clinicaltrials.gov/study/NCT05743075
  3. https://clinicaltrials.gov/study/NCT03443414
  4. https://clinicaltrials.gov/study/NCT03937479
  5. https://clinicaltrials.gov/study/NCT04535986
  6. https://clinicaltrials.gov/study/NCT02919995
  7. https://clinicaltrials.eu/trial/study-on-the-effects-of-ensifentrine-for-patients-with-non-cystic-fibrosis-bronchiectasis/
  8. https://clinicaltrials.gov/study/NCT02427165
  9. https://clinicaltrials.gov/study/NCT04527471
  10. https://clinicaltrials.gov/study/NCT04091360
  11. https://clinicaltrials.gov/study/NCT04027439
  12. https://clinicaltrials.gov/study/NCT02307162
  13. https://clinicaltrials.gov/study/NCT06460493
  14. https://clinicaltrials.gov/study/NCT05270525
  15. https://clinicaltrials.gov/study/NCT03028142
  16. https://clinicaltrials.gov/study/NCT03673670
  17. https://clinicaltrials.gov/study/NCT02542254
  18. https://clinicaltrials.gov/study/NCT07132983
  19. https://clinicaltrials.gov/study/NCT07016412